IGM Biosciences, Inc. financial data

Location
Mountain View, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q2 2025 - 31 Jul 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 597% % -27%
Debt-to-equity 286% % 144%
Return On Equity -93% % 22%
Return On Assets -24% % 56%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float $50,700,000 USD -62%
Weighted Average Number of Shares Outstanding, Basic 61,462,957 shares 1.7%
Weighted Average Number of Shares Outstanding, Diluted 61,751,283 shares 2.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $103,277,000 USD -47%
General and Administrative Expense $49,848,000 USD 10%
Operating Income (Loss) $61,881,000 USD 74%
Nonoperating Income (Expense) $8,496,000 USD -51%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $195,795,000 USD 20%
Income Tax Expense (Benefit) $0 USD -100%
Net Income (Loss) Attributable to Parent $53,385,000 USD 76%
Earnings Per Share, Basic 0 USD/shares 75%
Earnings Per Share, Diluted 0 USD/shares 75%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $30,649,000 USD -54%
Assets, Current $106,990,000 USD -60%
Property, Plant and Equipment, Net $0 USD -100%
Operating Lease, Right-of-Use Asset $0 USD -100%
Other Assets, Noncurrent $0 USD -100%
Assets $106,990,000 USD -68%
Accounts Payable, Current $2,398,000 USD -26%
Accrued Liabilities, Current $3,662,000 USD -86%
Liabilities, Current $6,060,000 USD -84%
Operating Lease, Liability, Noncurrent $0 USD -100%
Other Liabilities, Noncurrent $0 USD
Liabilities $6,060,000 USD -97%
Accumulated Other Comprehensive Income (Loss), Net of Tax $8,000 USD
Retained Earnings (Accumulated Deficit) $972,345,000 USD -5.8%
Stockholders' Equity Attributable to Parent $100,930,000 USD -18%
Liabilities and Equity $106,990,000 USD -68%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $32,519,000 USD 23%
Net Cash Provided by (Used in) Financing Activities $5,000 USD -97%
Net Cash Provided by (Used in) Investing Activities $42,736,000 USD 394%
Common Stock, Shares Authorized 1,200,000,000 shares 900%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $10,222,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $30,649,000 USD -54%
Deferred Tax Assets, Valuation Allowance $301,060,000 USD 13%
Deferred Tax Assets, Gross $312,207,000 USD 12%
Operating Lease, Liability $43,200,000 USD
Depreciation $2,272,000 USD 4.4%
Payments to Acquire Property, Plant, and Equipment $31,000 USD -99%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $53,182,000 USD 76%
Lessee, Operating Lease, Liability, to be Paid $56,795,000 USD 2.9%
Property, Plant and Equipment, Gross $61,821,000 USD 5.1%
Operating Lease, Liability, Current $0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two $7,319,000 USD 20%
Lessee, Operating Lease, Liability, to be Paid, Year One $7,759,000 USD -1.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $11,609,000 USD -5.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three $7,521,000 USD 21%
Deferred Tax Assets, Operating Loss Carryforwards $100,135,000 USD 36%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200,000,000 shares 0%
Unrecognized Tax Benefits $12,634,000 USD 20%
Lessee, Operating Lease, Liability, to be Paid, Year Four $7,484,000 USD 17%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%